[Phlebopathies: aetiology and therapeutic management]

Area of Science:

• Vascular Medicine
• Pharmacology
• Epidemiology

Context:

• Phlebopathy, a term often referring to functional venous disorders, can significantly impact quality of life.
• Hormone-induced phlebopathy is specifically linked to the long-term use of combined oral contraceptives (COCs).
• Understanding the management of COCs-induced venous insufficiency is crucial for women's health.

Purpose:

• To classify, understand the pathogenesis and epidemiology of phlebopathies.
• To evaluate the effectiveness of different management strategies for hormone-induced phlebopathy.
• To compare the outcomes of discontinuing COCs, using Antistax with compression, and continuing COCs with Antistax.

Summary:

• A study involving 112 women with hormone-induced phlebopathy compared three treatment groups: COC withdrawal alone, COC withdrawal with Antistax and compression, and continued COC use with Antistax.
• Objective measures (malleolar volume) and subjective assessments (symptoms, quality of life) were recorded.
• Results indicated that discontinuing COCs alone was insufficient; Antistax demonstrated efficacy in managing symptoms, even with continued COC use, with optimal results seen in combined therapy.

Impact:

• Discontinuation of COCs alone does not fully resolve phlebopathy symptoms.
• Antistax effectively alleviates most clinical manifestations of phlebopathy, even during ongoing COC use.
• The most significant improvement in hormone-induced phlebopathy was achieved through a combination of COC discontinuation, Antistax treatment, and elastic compression therapy.